Real-world outcomes of a novel presbyopia- correcting intraocular lens with a non-diffractive design implanted in patients with altered ocular surface (EVOLVE study)

Michael Lawless, Lily Yu-Li Chang, Caridad Pérez- Vives

Meeting:  2022 RANZCO


Date:      -


Session Time:      -

Purpose: To report the real-world clinical visual out- comes of AcrySof IQ Vivity™ extended depth-of-focus IOLs (models DFT015 and DFTX15-Toric) implanted in a subgroup of subjects with altered ocular surface.

Method: This is the first interim sub-analysis of the multicentre, ambispective registry EVOLVE study conducted in Europe, the UK and Australia. After a minimum of three months of follow-up (defined by local clinical practice standards), binocular uncorrected and best-distance corrected visual acuities (VA) at distance, intermediate (66 cm) and near (40 cm) were measured. Patient satis- faction were also reported using validated questionnaires, as well as non-prompted visual disturbances.

Results: To date, 20 patients with altered ocular surface have been implanted bilaterally with DFT015 or DFTX15-Toric IOL in this study. Altered ocular surface includes dry eye (n = 10), post-LASIK (n = 5), corneal dys- trophy (n = 4) and others (n = 3). Binocular mean Snellen distance VA was 6/6, intermediate VA was 6/7.5 and near VA was 6/9.5 for uncorrected and best-distance corrected. Moreover, high levels of subject satisfaction were reported: 85% of subjects reported they were fairly or very satisfied with their sight. In addition, no halos, glare or starbursts were reported by 90%, 80% and 90% of subjects, respectively.

Conclusion: This real-world assessment of subjects with altered ocular surface and bilaterally implanted with DFT015 or DFTX15-Toric IOL has shown good distance, intermediate and functional near visual outcomes, as well as high patient satisfaction and low levels of visual disturbances.